beta-Amyrin palmitate

Research use only, not for human use.

Beta-Amyrin palmitate may release norepinephrine from newly synthesized pools, and thus, it may activate noradrenergic activity.

Beta-Amyrin palmitate may release norepinephrine from newly synthesized pools, and thus, it may activate noradrenergic activity. Beta-Amyrin palmitate, like mianserin and imipramine, reduces the duration of immobility of mice significantly in a dose-dependent manner (5, 10 and 20 mg kg-1); (1)Beta-Amyrin palmitate or mianserin elicits a dose-related reduction in locomotor activity of mice and antagonizes locomotor stimulation induced by methamphetamine, imipramine increases locomotor activity and potentiates methamphetamine-induced hyperactivity; (2)Beta-Amyrin palmitate shows no effect on reserpine-induced hypothermia, whilst mianserin (10 mg kg-1) and imipramine (10 and 20 mg kg-1) antagonizes the reserpine-induced effect; (3)Beta-amyrin palmitate has similar properties in some respects to mianserin and might possess a sedative action.

Others

Other Targets

LDL | HMG-CoA Reductase | Adrenergic Receptor

——

——

5973-6-8

665.1

C46H80O2

>98% (HPLC)

DMSO, Pyridine, Methanol, Ethanol, etc.

——

(-20℃)

With Ice Pack

≥ 2 years